McKinsey’s Push For Class-Wide Opioid REMS Among Actions Targeted In Opioid Settlement
Executive Summary
Consulting firm agrees to turn over tens of thousands of documents detailing its advice to Purdue, J&J, Endo and Mallinckrodt and pay $537m as part of a deal with 47 states.
You may also be interested in...
Purdue's $8.3bn Settlement With DOJ Requires Reconstitution As Public Benefit Company
Purdue pleads guilty to three felony charges over marketing of OxyContin under settlement that requires Purdue to be dissolved and transformed into an entity that provides addiction and overdose medicines. Twenty-five state AGs oppose creation of a PBC, arguing Purdue should be sold to another company.
Purdue's Opioid Rescue Drug Development To Continue Under A New Company
Purdue proposes continuing the development of nalmefene hydrochloride and other products under a new company that would provide the products at no or low cost.
Will Purdue Bankruptcy Filing Resolve 'Unrelenting Chaos' Of Opioid Litigation?
Filing stays litigation but state attorneys general will be battling company's settlement proposal in US bankruptcy court. Details emerge on Purdue finances, rebate expenditures and litigation costs.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: